<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134666">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02147379</url>
  </required_header>
  <id_info>
    <org_study_id>H14-00290</org_study_id>
    <nct_id>NCT02147379</nct_id>
  </id_info>
  <brief_title>Lurasidone and Cognition in Bipolar I Disorder</brief_title>
  <official_title>Changes in Cognitive Functioning in Euthymic Bipolar Patients Treated With Lurasidone Versus Treatment as Usual; A Randomized, Open-Label Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 6 week, randomized, open-label, parallel group study in patients with Bipolar-I
      disorder (manic depression), who are in remission from an episode. Participants who show
      cognitive impairment at baseline will be randomized to receive open-label Lurasidone added
      on to their current medication(s) or continue their usual treatment for 6 weeks.
      Participants will have 3 clinical visits and 2 telephone appointments during the study.
      Given the preliminary evidence for efficacy of Lurasidone in improving cognition in
      schizophrenia, we propose to examine the efficacy of Lurasidone in improving cognition in
      bipolar patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Cognitive Change in Bipolar I disorder after treatment with Lurasidone</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The International Society for Bipolar Disorders-Battery for Assessment of Neurocognition (ISBD-BANC) will be administered to assess cognitive functioning at baseline and at endpoint ( change in scores on cognitive tests)  to evaluate the efficacy of lurasidone on cognitive changes in bipolar disorder.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Bipolar I Disorder</condition>
  <arm_group>
    <arm_group_label>Lurasidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lurasidone 20 - 80 mg / day added to current treatment for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as usual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients randomized to this arm will continue their usual treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lurasidone</intervention_name>
    <arm_group_label>Lurasidone</arm_group_label>
    <other_name>Latuda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients must be taking either lithium or valproate or one of the atypical
             antipsychotics for mood stabilization.

          2. Patients who show cognitive impairments (-0.75 standard deviations (SD) or below) on
             either the Trail Making Test- trial B (TMT-B) or California Verbal Learning Test
             trials 1 to 5, at baseline visit.

          3. Males or females aged 19 to 55 years inclusive.

          4. Diagnostic and Statistical Manual IV edition (DSM-IV TR) diagnosis of Bipolar Type I
             Disorder, with or without a history of psychosis.

          5. Clinically stable with a Montgomery Asberg Depression Rating Scale (MADRS) and Young
             Mania Rating Scale (YMRS) score less than or equal to 8.

          6. A sufficient level of English using a language screening questionnaire.

          7. Capability of understanding, consenting to, and complying with the requirements of
             the study.

        Exclusion Criteria:

          1. A history of unstable or inadequately treated medical illnesses, including moderate
             to severe brain injury, or neurological illnesses impacting cognitive function.

          2. Treatment with Electroconvulsive Therapy (ECT) within eight weeks prior to enrolment;
             or treatment with an experimental drug within 30 days prior to enrolment.

          3. Axis I diagnosis of substance abuse or dependence within the past month.

          4. Significant risk of harm to self or others, in the opinion of the investigator.

          5. Pregnancy or lactation in female subjects.

          6. Liver function tests (AST and ALT) three times the upper limit of normal. -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lakshmi N Yatham, MBBS, FRCPC, MRCPsych (UK), MB</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nazlin Walji, BSc</last_name>
    <phone>604-822-7294</phone>
    <email>nazlin.walji@ubc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sylvia Mackala, BA Hons</last_name>
    <phone>604-822-7954</phone>
    <email>sylvia.mackala@ubc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of British Columbia, Department of Psychiatry</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nazlin Walji, BSc</last_name>
      <phone>604-822-7294</phone>
      <email>nazlin.walji@ubc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Sylvia Mackala</last_name>
      <phone>604-822-7954</phone>
      <email>sylvia.mackala@ubc.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>May 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Cognition</keyword>
  <keyword>Euthymic</keyword>
  <keyword>Lurasidone</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
